Despite advances in electronic medication order entry systems, it has been well established that clinicians override many drug allergy alerts generated by the electronic health record. The direct clinical consequences of overalerting clinicians in a pediatric setting have not been well demonstrated in the literature. We observed a patient in the PICU who experienced complications as a result of an extended series of non-evidence-based alerts in the electronic health record. Subsequently, evidence-based allergy alerting changes were made to the hospital' s system. Incorporating clinical evidence in electronic drug allergy alerting systems remains challenging, especially in pediatric settings. Pediatrics 2013;131:e1970-e1973 
Although adoption of electronic health records (EHRs) with integrated computerized clinical decision support systems (CDSS) has decreased hospital errors and risks to patients, 1,2 the optimal technological implementation of these systems remains elusive. One such area of concern is how to best alert physicians of allergy-induced preventable adverse drug events (ADEs) when entering drug orders electronically, 3 especially for pediatric patient populations for whom drug allergy prevalence varies substantially from adults. 4 An important subset of preventable ADEs frequently targeted by CDSS is drug allergy crossreactivity; however, a paucity of evidence regarding the efficacy of such alerts in practice remains. 5 A barrier to effective alerting systems is the large number of inappropriate alerts, leading to widespread override of medication alerts by providers. Clinician overrides of drug allergy alerts in settings, such as the Department of Veterans Affairs, 6 tertiary medical centers, 7 and outpatient ambulatory clinics, 8 demonstrate that between 69% and 91% of alerts are overridden. Most allergy alerts do not provide clinically significant information that alters the clinician' s care because the alerts are based on unlikely potential cross sensitivities or on incorrectly entered allergy data. 7 This situation creates far too many false-positive alerts, 9 which leads to alert fatigue. More than a mere nuisance for health care providers, alert fatigue has been defined as "declining clinician responsiveness to a particular type of alert as the clinician is repeatedly exposed to that alert over a period of time, gradually becoming 'fatigued' or desensitized to it." 10 Electronic alert fatigue renders CDSS less effective and presents a serious patient safety issue, 11 as demonstrated by a recent clinical case in the PICU at Lucile Packard' s Children' s Hospital.
PATIENT PRESENTATION
A 2-year-old boy with a history of short gut syndrome due to gastroschisis, total parenteral nutrition-associated cholestasis, status post liver, and small bowel transplantation 5 months prior was admitted to the PICU with respiratory distress and rash of unclear etiology. Although he had a documented sulfonamide antibiotic allergy in the EHR, he required treatment with both chlorothiazide and furosemide during the course of his inpatient hospitalization. Each time the 2 diuretics were indicated and administered during the hospitalization, alerts based on potential drug allergy cross reactivity would be generated, as shown in Fig 1. The clinical team overrode those alerts based on strong evidence suggesting that cross-reactivity of these medications is not the basis for hypersensitivity. 12 The various clinical staff that appropriately ordered and administered this patient' s medications overrode more than 100 alerts over a 1-month time frame.
During the hospital course, the patient' s rash became exfoliating and more extensive, eventually involving more than 60% of his body surface area. Dermatology, plastics, and allergy/ immunology services were consulted. Based on the results of a skin biopsy, the primary differential diagnosis for the rash was a drug hypersensitivity reaction versus graft-versus-host disease. Given the concern for a true allergic hypersensitivity to furosemide, a furosemide allergy was documented in the record in addition to the preexisting sulfonamide antibiotic allergy. Desensitization to EHR drug alerting by the deluge of overrides, however, resulted in temporary continued administration, over the course of 1 night, of the now inappropriate furosemide medication. This event complicated the evaluation and treatment of his worsening, desquamating rash.
Based on the differential diagnosis, the patient' s immunosuppression was increased to treat possible graft-versushost disease and further allergy studies were pursued. A basophil activation assay was performed on the patient' s blood against sulfonamide drugs. This test revealed that he did not have a Type I immunoglobulin E-mediated hypersensitivity allergic response to sulfonamide. However, this test did not rule out allergic reactions to sulfonamide metabolites or either Type III or Type IV hypersensivities to sulfonamide medications. Given the patient' s worsening clinical status, clinicians decided to cautiously administer several sulfonamide-containing medications (both antimicrobial agents and diuretics). He appeared to tolerate these medications well with continued positive response to his immunosuppressive regimen, suggesting that he did not, in fact, have allergy to the medications. Unfortunately, the patient eventually died after developing fungal pneumonia with subsequent respiratory failure and septic shock.
DISCUSSION
Although the patient' s clinical course was complicated by many factors, the inappropriate allergy overrides further confused the situation. The solution to the problem of drug allergy alert overrides and the ensuing alert fatigue encompasses many sociotechnical 13 aspects of clinical health systems, such as ensuring provider education on how to document allergy, incorporating evidence-based medicine into health information systems, and unifying medication allergies into a single digital location. Implementing clinical evidence-based drug crossreactivity rules into health information systems, rather than relying on pharmacologic moiety-driven databases, poses several important challenges. These databases come built into the software of many vendor-based EHR systems and are often unchanged to accommodate new clinical evidence. The terminology 14 and true incidence of substance intolerance, especially in pediatric medicine, lacks clarity in many respects. Moreover, the timedependent nature of adverse drug reactions makes data-driven prediction of effects challenging, although there has been significant recent progress. 15 Excessive electronic alerts warning clinicians of potential but rare adverse drug cross reactions result in increased patient safety risks by rendering these alerts meaningless. The challenge of omitting specific drug cross-reactivity pairings from CDSS raises appropriate questions of ensuring proper sensitivity for detection of true allergy-based ADEs. Careful consideration to eliminate medication pairings alerts that pose a minimal theoretical risk of true hypersensitivity is critical. This was done at Lucile Packard' s Children' s Hospital as a result of this clinical case to ensure adequate attention is paid to legitimate alerts. Staff physicians, pharmacists, and informaticists worked with the EHR vendor to modify and improve the allergy alerting system. These enhancements included a streamlined approach to allergy entry, distinguishing between allergy alerts for sulfonamide antibiotics and nonantibiotics, enhanced alerts to nursing staff, and staff education. Turning off improper alerts in practice has been challenging, as a direct result of variation in physician drug-related knowledge and hospital drug-monitoring routines. 16 Uncertainty about drug reaction severity, 17 legal concerns, and regulatory mandates with public reporting implications 18 further complicate implementation of smarter alerting systems.
From a malpractice perspective, the creation of a tort "safe haven" would rightly recognize that experimentation with evidence-based CDSS software systems could protect both clinicians and software vendors in an overall effort to improve patient safety. 19 Although new international guidelines designed to identify the most important drug warnings 20 could assist this process, regulation and rigorous evaluation of clinical information systems are by no means one and the same. 21 As recently remarked, 22 the payoffs of information technology investment come only after intensive process reengineering, a formidable task in the pediatric setting.
CONCLUSIONS
As the medical community increasingly embraces clinical decision support tools and electronic drug order entry safeguards, there must be a heightened awareness of overalerting risks to patient well-being. The threat of missing a rare event must be balanced with the dangers of burdening clinicians with unnecessary and interruptive electronic alerts. True evidence-based medicine must rely on risk mitigation on both sensitivity and specificity fronts if the full potential of health information technology can be realized. Analogous to ICU alarm fatigue, this article shows the clinical consequences of EHR alert fatigue on patient health.
